Among them, the most striking results included the potential reduction in the likelihood of secondary hyperparathyroidism and microbial infections such as tuberculosis, as well as an increase in CD4+ T lymphocytes count and a decrease in biomarkers associated with bone turnover and chronic inflammation. The gene discussed is CD4; the disease is secondary hyperparathyroidism.